Caribou Biosciences to Participate in Upcoming Investor Conferences
May 31 2023 - 4:00PM
Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading
clinical-stage CRISPR genome-editing biopharmaceutical company,
today announced Rachel Haurwitz, PhD, Caribou’s president and chief
executive officer, is scheduled to present at the following
investor conferences during the month of June:
- Jefferies Healthcare Conference, New
York, NYJune 7, 2023, 3:00 pm EDTWebcast
- Goldman Sachs 44th Annual Global
Healthcare Conference, Dana Point, CAJune 13, 2023, 3:20 pm
PDTWebcast
For more information, visit the Events page on Caribou’s
website. Webcasts will be available on the Caribou website for 30
days after the event.
About Caribou’s Novel Next-Generation CRISPR
PlatformCRISPR genome editing uses easily designed,
modular biological tools to make DNA changes in living cells. There
are two basic components of Class 2 CRISPR systems: the nuclease
protein that cuts DNA and the RNA molecule(s) that guide the
nuclease to generate a site-specific, double-stranded break,
leading to an edit at the targeted genomic site. CRISPR systems
have exhibited editing at unintended genomic sites, known as
off-target editing, which may lead to harmful effects on cellular
function and phenotype. In response to this challenge, Caribou has
developed CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced
“chardonnays”) that direct substantially more precise genome
editing compared to all-RNA guides. Caribou is deploying the power
of its Cas12a chRDNA technology to carry out high efficiency
multiple edits, including multiplex gene insertions, to develop
CRISPR-edited therapies.
About Caribou Biosciences, Inc.Caribou
Biosciences is a clinical-stage CRISPR genome-editing
biopharmaceutical company dedicated to developing transformative
therapies for patients with devastating diseases. The company’s
genome-editing platform, including its Cas12a chRDNA technology,
enables superior precision to develop cell therapies that are
armored to potentially improve antitumor activity. Caribou is
advancing a pipeline of off-the-shelf cell therapies from its CAR-T
and CAR-NK platforms as readily available treatments for patients
with hematologic malignancies and solid tumors. Follow us
@CaribouBio and visit www.cariboubio.com.
Caribou Biosciences, Inc.
Contacts:Investors:Amy Figueroa,
CFAinvestor.relations@cariboubio.com
Media:Peggy Vorwald,
PhDmedia@cariboubio.com
Caribou Biosciences (NASDAQ:CRBU)
Historical Stock Chart
From Jun 2024 to Jul 2024
Caribou Biosciences (NASDAQ:CRBU)
Historical Stock Chart
From Jul 2023 to Jul 2024